Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Leadership Team

- Leonard S. Schleifer, MD, PhD
  President and Chief Executive Officer
  + Fellow, American Association for the Advancement of Science (AAAS)

- George D. Yancopoulos, MD, PhD
  President and Chief Scientific Officer
  + Member, National Academy of Sciences

- P. Roy Vagelos, MD
  Chairman of the Board
  + Former Chief Executive Officer and Chairman of the Board, Merck & Co.
  + Member, National Academy of Sciences

- Board of Directors includes two Nobel Laureates and seven members of the National Academy of Sciences

FDA-Approved & Marketed Medicines*

1. Arcalyst® (riluzumab) Injection for Subcutaneous Use
2. Dupixent® (dupilumab) Injection 100 mg, 200 mg, 300 mg
3. Evkeeza® (evinacumab-drgn) Injection
4. Eylea® ( aflibercept) Injection
5. Inmazeb® (atoltivimab, maftivimab, and odesivimab-ebgn)
6. Kevzara® (sarilumab) Injection 150 mg, 200 mg
7. Libtayo® (cemiplimab-rwlc) Injection
8. Praluent® (alirocumab) Injection
9. Zaltrap® (ziv-aflibercept)

* U.S. Food and Drug Administration

1. In collaboration with Sanofi outside of U.S. For Praluent, in collaboration with Sanofi prior to April 2020; effective April 2020, Regeneron is solely responsible for the U.S. development and commercialization and Sanofi is solely responsible for the ex-U.S. development and commercialization of Praluent.
Clinical Product Candidates

PHASE 1
- ALN-HSD
- FIANLIMAB
- NTLa-2001
- ODNRTENAMAB
- REGN4018
- REGN4336
- REGN5093
- REGN5093-M114
- REGN5381
- REGN5459
- REGN5668
- REGN5678
- REGN6490
- REGN6569
- REGN7075
- REGN7257
- REGN9933

PHASE 2
- AFLIBRECEPT 8 MG
- CEMDISIRAN
- CEMIPLIMAB
- DIPULUMAB
- DUPLIMAB
- EVINACUMAB
- GARETOSMAB
- ODRONEXTAMB
- POZELIMAB
- SARILUMAB
- CEMIPLIMAB
- GARETOSMAB
- POZELIMAB

PHASE 3
- DUPLUSMAB
- ACRILIMAB
- INTEKIMAB
- POZELIMAB
- REGN1908-1909

In collaboration with:
- Sanofi
- Teva and Mitsubishi Tanabe
- Bayer
- Intellia
- Alexion
- Roche

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

Leaders in Technology

Fully human monoclonal antibodies
Regeneron has developed a suite of patented technologies (VelociSuite™), including VelociGene®, VelocImmune® and VelociMab®, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

Fusion proteins
Our novel and patented “Trap” fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

Regeneron Genetics Center®
A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Fast Company: Best Workplaces for Innovators, 2021
Great Place To Work: Fortune 100 Best Companies to Work For, 2021
Great Place to Work Ireland: Best Workplaces, 2021
Great Place to Work Ireland: Best Workplaces for Women, 2021
Fast Company: World Changing Ideas (Pandemic Response), 2021
IDEA Pharma: Pharmaceutical Invention Index, 2021
Science: Top Employer, 2021

To learn more about us, please visit:
REGENERON.COM  @REGENERON

Regeneron Genetics Center, Science to Medicine, VelociGene, VelociSuite, VelocImmune, VelociMab, ARCALYST, EYLEA and LIBTAYO are registered trademarks of Regeneron Pharmaceuticals, Inc. in the U.S.; Praluent and Dupixent are registered trademarks of Sanofi.
© Regeneron Pharmaceuticals, Inc. 2/22